ALKEM:NSE-Alkem Laboratories Limited (INR)

COMMON STOCK | Drug Manufacturers-Specialty & Generic | NSE

Last Closing Price

INR 2,842.10

Change

-72.55 (-2.49)%

Market Cap

INR 348.49B

Volume

0.22M

Average Target Price

INR 3,361.75 (+18.28%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Alkem Laboratories Limited, a pharmaceutical company, develops, manufactures, and sells pharmaceutical and nutraceutical products in India and internationally. The company offers branded generics, generic drugs, active pharmaceutical ingredients, and nutraceuticals in acute and chronic therapeutic areas comprising anti-infective, dermatology, diabetology, cardiology, gastroenterology, osteoporosis, central nervous system, oncology, urology, and gynaecology, as well as vitamins, minerals, and nutrients; and pain relief/analgesic, anti-diabetic, and neurology products. It also provides pregnancy detection kits and condoms. Alkem Laboratories Limited was founded in 1973 and is headquartered in Mumbai, India. Address: Devashish Building, Mumbai, India, 400013

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-03-03 )

Largest Industry Peers for Drug Manufacturers-Specialty & Generic

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
SUNPHARMA:NSE Sun Pharmaceutical Industries ..

+10.15 (+1.65%)

INR1,473.67B 61.16 29.76
DIVISLAB:NSE Divi's Laboratories Limited

+48.25 (+1.37%)

INR933.63B 49.91 35.83
DRREDDY:NSE Dr. Reddy's Laboratories Limit..

+97.85 (+2.22%)

INR730.89B 34.46 18.07
AUROPHARMA:NSE Aurobindo Pharma Limited

-5.40 (-0.61%)

INR519.08B 9.64 6.18
LUPIN:NSE Lupin Limited

+6.35 (+0.60%)

INR478.13B 41.85 16.71
CADILAHC:NSE Cadila Healthcare Limited

+4.40 (+1.00%)

INR451.67B 24.47 15.93
IPCALAB:NSE Ipca Laboratories Limited

+54.70 (+2.87%)

INR241.88B 22.66 14.85
LAURUSLABS:NSE Laurus Labs Limited

+2.70 (+0.75%)

INR194.17B 24.36 15.57
APLLTD:NSE Alembic Pharmaceuticals Limite..

-5.60 (-0.60%)

INR183.65B 15.57 11.43
AJANTPHARM:NSE Ajanta Pharma Limited

-8.10 (-0.46%)

INR151.78B 24.39 15.14

ETFs Containing ALKEM

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers-Specialty & Generic)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -3.68% 50% F 28% F
Dividend Return 0.85% 30% F 48% F
Total Return -2.83% 50% F 30% F
Trailing 12 Months  
Capital Gain 11.47% 10% F 21% F
Dividend Return 1.10% 79% C+ 52% F
Total Return 12.56% 10% F 22% F
Trailing 5 Years  
Capital Gain 116.74% 69% D+ 75% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 116.74% 69% D+ 74% C
Average Annual (5 Year Horizon)  
Capital Gain 17.50% 69% D+ 78% C+
Dividend Return 0.60% 67% D+ 45% F
Total Return 18.10% 68% D+ 78% C+
Risk Return Profile  
Volatility (Standard Deviation) 23.56% 95% A 82% B-
Risk Adjusted Return 76.83% 94% A 94% A
Market Capitalization 348.49B 91% A- 93% A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers-Specialty & Generic)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 22.72 48% F 46% F
Price/Book Ratio 4.65 33% F 19% F
Price / Cash Flow Ratio 59.56 17% F 7% F
EV/EBITDA 14.88 41% F 41% F
Management Effectiveness  
Return on Equity 22.57% 75% C 92% A-
Return on Invested Capital 16.63% 84% B 88% B+
Return on Assets 10.52% 77% C+ 93% A
Debt to Equity Ratio 1.10% 68% D+ 76% C
Technical Ratios  
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta 0.36 82% B- 92% A-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (INR)

Quarterly Financials (INR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.